{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:54:51Z","timestamp":1781826891719,"version":"3.54.5"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) harboring ALK fusions is exceptionally rare, with limited data on clinical outcomes with ALK inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 70-year-old man presented with stage IV PDAC (pancreatic tail primary with liver and lymph node metastases). Following progression on first-line gemcitabine\/nab-paclitaxel, tumor next-generation sequencing identified an ITSN1-ALK fusion (62.12% abundance) and TP53 mutation. The patient received alectinib 600\u2009mg twice daily beginning at Month 4. Tumor markers declined markedly (CA19-9 from 234 to 12.7 U\/mL by Month 7), and radiographic stability was maintained through Month 22. Upon progression at Month 23, treatment was switched to lorlatinib followed by capecitabine plus nimotuzumab. The patient remains alive at last follow-up (Month 29). Progression-free survival on alectinib was 19\u2009months\u2014substantially exceeding the median of 5.0\u2009months reported for ALK fusion-positive gastrointestinal cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This first report of ITSN1-ALK fusion in PDAC demonstrates that ALK inhibition can produce durable, clinically meaningful benefit. This case reinforces the importance of comprehensive genomic profiling in KRAS-wildtype PDAC to identify actionable rare fusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for practice<\/jats:title>\n                    <jats:p>Oncologists should consider broad next-generation sequencing, including fusion detection, for patients with KRAS-wildtype PDAC. When an ALK fusion is identified, ALK inhibitor therapy can yield durable disease control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag209","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:17:23Z","timestamp":1779794243000},"source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-3312","authenticated-orcid":false,"given":"Chaoxing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shijiazhuang People\u2019s Hospital , Shijiazhuang, Hebei Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shijiazhuang People\u2019s Hospital , Shijiazhuang, Hebei Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shijiazhuang People\u2019s Hospital , Shijiazhuang, Hebei Province,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2026061819461806400_oyag209-B1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2026061819461806400_oyag209-B2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2026061819461806400_oyag209-B3","doi-asserted-by":"publisher","first-page":"e2200015","DOI":"10.1200\/PO.22.00015","article-title":"ALK inhibitors in patients with ALK fusion-positive GI cancers: an international data set and a molecular case series","volume":"6","author":"Ambrosini","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026061819461806400_oyag209-B4","doi-asserted-by":"publisher","first-page":"12510","DOI":"10.1038\/s41598-017-12679-8","article-title":"Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches","volume":"7","author":"Vendrell","year":"2017","journal-title":"Sci Rep"},{"key":"2026061819461806400_oyag209-B5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3580","article-title":"Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology","volume":"13","author":"Hallberg","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2026061819461806400_oyag209-B6","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann Oncol"},{"key":"2026061819461806400_oyag209-B7","doi-asserted-by":"publisher","first-page":"PO.19.00365","DOI":"10.1200\/PO.19.00365","article-title":"Novel ALK fusion, PPFIBP1-ALK, in pancreatic ductal adenocarcinoma responsive to alectinib and lorlatinib","volume":"4","author":"Gower","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2026061819461806400_oyag209-B8","doi-asserted-by":"publisher","first-page":"724815","DOI":"10.3389\/fonc.2021.724815","article-title":"ALK rearrangement-positive pancreatic cancer with brain metastasis has remarkable response to ALK inhibitors: a case report","volume":"11","author":"Ou","year":"2021","journal-title":"Front Oncol"},{"key":"2026061819461806400_oyag209-B9","doi-asserted-by":"publisher","first-page":"e2100400","DOI":"10.1200\/PO.21.00400","article-title":"Exceptional clinical response to alectinib in pancreatic acinar cell carcinoma with a novel ALK-KANK4 gene fusion","volume":"6","author":"Gaule","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026061819461806400_oyag209-B10","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061819461806400_oyag209-B11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.6004\/jnccn.2017.0058","article-title":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","volume":"15","author":"Singhi","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2026061819461806400_oyag209-B12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1634\/theoncologist.2016-0194","article-title":"An oncogenic ALK fusion and an RRAS mutation in KRAS mutation-negative pancreatic ductal adenocarcinoma","volume":"22","author":"Shimada","year":"2017","journal-title":"Oncologist"},{"key":"2026061819461806400_oyag209-B13","doi-asserted-by":"publisher","first-page":"757965","DOI":"10.3389\/fonc.2021.757965","article-title":"Case report: a pancreatic ductal adenocarcinoma patient with concurrent targetable somatic novel KANK1-ALK, UPP2-NTRK3 fusion, and pathogenetic germline BRCA mutation","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag209\/68413817\/oyag209.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag209\/68413817\/oyag209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag209\/68413817\/oyag209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:46:21Z","timestamp":1781826381000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag209\/8696449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag209","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,27]]},"article-number":"oyag209"}}